BG Medicine - Gilde Healthcare

BG Medicine


Waltham (MA), USA

Molecular Diagnostics in heart failure
Since: 2002
Exit: 2011

BG Medicine markets molecular diagnostic tests for cardiovascular diseases. BG Medicine’s lead product is the Galectin-3® test, a simple and affordable blood test that helps predict the condition of patients with chronic heart failure. Approved by the US Food and Drug Administration, the Galectin-3® test can identify heart patients that are at especially high risk of hospitalization and death.

Gilde joined BG Medicine in the Series-A investment round, when it was founded on intellectual property from the Massachusetts Institute of Technology (MIT) and TNO Pharma, based in the Netherlands. The company has since transitioned from a business-to-business service model to becoming a diagnostic product company and successfully listed on NASDAQ (BGMD) through an IPO in 2011.

The Galectin-3® test is sold in the United States and in Europe. In order to commercialize automated versions of the Galectin-3® test, Massachusetts-based BG Medicine has partnered with major manufacturers of diagnostic instruments, including Abbott, BioMerieux and Siemens.

More BG Medicine news

BG Medicine Announces FDA 510(k) Clearance of its Galectin-3 Test

BG Medicine, Inc. Files 510(k) for a diagnostic test to predict heart attacks

BG Medicine, Inc. Names Stephen R. Miller Chief Commercial Officer

BG Medicine Named To Russell 3000 Investment Index

BG MEDICINE announces Research Agreement with Boston Scientific on Cardiovascular Biomarkers

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

BG Medicine exercises over-allotment option and closing of IPO

BG Medicine Announces Pricing of Initial Public Offering at NASDAQ

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

BG Medicine and Siemens Healthcare Diagnostics to Develop Galectin-3 Test

Inverness Medical and BG MEDICINE to Develop Galectin-3 Test for Inverness’ Triage® Meter

BG Medicine and Abbott to Develop Galectin-3 Test for the i-STAT® System

BG MEDICINE files Registration Statement for proposed Initial Public Offering at NASDAQ

BG Medicine Announces Receipt Of CE Mark For Its Galectin-3 Blood Test

BG MEDICINE and Abbott announce a development and commercialization agreement for galectin-3 biomark

BG MEDICINE and Humana Enroll More Than 6,800 Participants in BioImage Study

BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service

BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics

BG MEDICINE Announces Publication of Biomarker Signature of Atherosclerotic Plaque Rupture

BG Medicine Closes $40 Million in Series D Financing

BG Medicine announces collaboration with Takeda to Discover Biomarkers of High-Risk Atherosclerotic

BG Medicine and Copenhagen General Population Study Initiate Biomarker Discovery

BG Medicine Acquires Exclusive Commercial Rights to Biomarker of Vascular Plaque Rupture